U.S. Food and Drug Administration Approves ORKAMBI(R) (lumacaftor/ivacaftor) for Use in Children with Cystic Fibrosis Ages 6 through 11 who have Two Copies of the F508del Mutation

Read also

Takeda

Takeda walks away from cell therapy in priority U-turn

Taysha Says

Taysha Says FDA Grants Breakthrough Therapy Designation To In Rett Syndrome

Intravitreal Injection of Retinal Progenitor

Intravitreal Injection of Retinal Progenitor Cells Shows Promise in Preclinical Study for Diabetic Retinopathy

Mercury Bio

Mercury Bio Reports Positive Results from Preclinical Study Evaluating Novel Drug Delivery Technology Transporting Protein